系统A氨基酸转运PET成像在同系小鼠模型中检测免疫检查点抑制剂早期应答
该研究在MC38同系小鼠模型中比较18F-MeFAMP与18F-FDG PET/CT在双ICI治疗前及治疗后6天检测肿瘤摄取,发现18F-FDG无论应答与否均无显著差异,而18F-MeFAMP SUV40%在应答者中显著下降(-60.0%±15.6%,P<0.0001),非应答者无显著变化(+45.5%±51.2%,P=0.09),且18F-MeFAMP在肝、肺、脑等常见转移部位摄取低。
要点
- 18F-FDG在ICI治疗前后无论应答与否均无显著差异
- 18F-MeFAMP SUV40%在应答者中显著下降60.0%±15.6%(P<0.0001)
- 18F-MeFAMP在肝、肺、脑等常见转移部位摄取低
核心结论
- 18F-MeFAMP比18F-FDG更好地检测ICI早期应答,且全身成像特性良好。
研究设计与样本
- 在MC38同系雌性C57BL/6小鼠模型中,用PET/CT比较双ICI治疗前及治疗后6天肿瘤对18F-MeFAMP与18F-FDG的摄取。
主要发现
- 18F-FDG在基线或ICI治疗后无论应答与否均无显著差异。
- 18F-MeFAMP SUV40%在应答者中显著下降(-60.0%±15.6%,P<0.0001),非应答者无显著变化(+45.5%±51.2%,P=0.09)。
- 18F-MeFAMP的SUVmax、生物肿瘤体积和总病灶活性呈现类似模式。
- 直方图分析显示两组间18F-MeFAMP摄取在成像前后有显著差异(P<0.05)。
- 18F-MeFAMP在肝、肺、脑等常见转移部位摄取低。
关键数值与推荐
- 18F-MeFAMP SUV40%定义为SUVmax的40%阈值。
- 应答者18F-MeFAMP SUV40%变化为-60.0%±15.6%(P<0.0001),非应答者为+45.5%±51.2%(P=0.09)。
临床怎么用
- 18F-MeFAMP PET/CT有望用于ICI治疗早期区分应答者与非应答者,以支持治疗强化或更换方案。
局限性
- 证据来自MC38同系小鼠模型,尚未在人体验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitor (ICI) therapy is effective and in routine clinical use for various cancers, but accurately identifying which patients will respond remains a significant challenge. The PET agent 18F-FDG has uptake by cancer cells as well as inflammation induced by ICI therapy, complicating and often limiting the utility of 18F-FDG for early response assessment during ICI therapy. An imaging agent that accurately distinguishes responders from nonresponders early in the course of ICI therapy could enable intensification or change of therapy for nonresponders. In this study, the 18F-labeled amino acid 18F-MeFAMP, a fluorinated analog selectively targeting system A amino acid transport, was compared with 18F-FDG in the MC38 syngeneic mouse model of ICI therapy. 18F-MeFAMP was chosen because of the relatively low uptake of system A substrates in inflammatory tissues combined with growing evidence suggesting system A transporters are involved in immunotherapy. Methods: PET/CT imaging was used to compare tumor uptake of 18F-MeFAMP with tumor uptake of 18F-FDG before and 6 d after starting dual ICIs in MC38 tumor-bearing female C57BL/6 mice. SUVs, biologic tumor volumes, and total lesion activity were measured along with selected tumor-to-organ ratios. Histogram analysis of tracer uptake was performed to assess differences in tumor activity distribution between responders and nonresponders. Results: 18F-FDG showed no significant differences at baseline or after ICI regardless of response. In contrast, 18F-MeFAMP SUVs defined using a 40% of SUVmax threshold (SUV40%) decreased significantly in responders (-60.0% ± 15.6%, P < 0.0001), whereas nonresponders showed no significant change (+45.5% ± 51.2%, P = 0.09). Similar patterns were observed with SUVmax, biologic tumor volume, and total lesion activity measures with 18F-MeFAMP. Histogram analysis revealed significant 18F-MeFAMP uptake differences between groups before and after imaging (P < 0.05). 18F-MeFAMP demonstrated low uptake in common metastatic sites, including liver, lungs, and brain. Conclusion: 18F-MeFAMP better detected early ICI response than 18F-FDG with favorable whole-body imaging properties. These findings support further investigation of 18F-MeFAMP for early evaluation of response to ICI and the role of system A substrates in cancer and immune cells before and during ICI.
引用
- Akca U, Zhang Y, Yasui N, et al. PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model. J Nucl Med. 2025. PMID: 41130795. doi:10.2967/jnumed.125.270466
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。